One Shot to Lower Cholesterol Forever: Verve's Base Editing Heart Trial Results

Heart disease kills more than 700,000 Americans every year. It is the leading cause of death in the United States, in Europe, and across much of the world. For decades, the standard defense has been a daily pill: statins, the blockbuster class of cholesterol-lowering drugs that generate over $20 billion in annual revenue worldwide. Millions of people take them. Millions more should but do not, because they forget, because they experience side effects, or because they simply stop filling prescriptions. The result is a slow-motion public health catastrophe — preventable heart attacks and strokes that claim lives year after year.

What if you could replace a lifetime of daily pills with a single intravenous infusion? What if one treatment, administered in under an hour, could permanently rewrite a gene in your liver and lower your cholesterol for good?

That is the promise of base editing applied to cardiovascular disease. And in early 2026, a company called Verve Therapeutics — now backed by pharmaceutical giant Eli Lilly — delivered clinical trial results suggesting it might actually work. Their drug, VERVE-102, reduced LDL cholesterol by up to 69% in patients with an inherited form of dangerously high cholesterol. There were zero treatment-related serious adverse events. The edit appears durable. And unlike every cholesterol drug before it, this one is designed to work once and never need repeating.

This is the story of how a single-letter change in a single gene could reshape the future of heart disease.

The Cholesterol Problem: Why We Need Better Solutions

The Scale of Cardiovascular Disease

Cardiovascular disease (CVD) remains the number-one killer globally, responsible for an estimated 17.9 million deaths per year according to the World Health Organization. In the United States alone, someone has a heart attack every 40 seconds. The economic burden is staggering — the American Heart Association estimates that CVD costs the U.S. healthcare system more than $400 billion annually in direct medical expenses and lost productivity.

At the root of much of this disease lies low-density lipoprotein cholesterol (LDL-C), commonly called "bad cholesterol." Elevated LDL-C drives the formation of atherosclerotic plaques — fatty deposits that narrow arteries, restrict blood flow, and can rupture to cause heart attacks and strokes. The relationship between LDL-C and cardiovascular risk is one of the most robustly established in all of medicine: lower LDL-C means fewer heart attacks, full stop.

Familial Hypercholesterolemia: A Genetic Time Bomb

For most people, high cholesterol is a product of diet, lifestyle, and aging. But for roughly 1 in 250 people worldwide, dangerously elevated LDL-C is hardwired into their DNA. These individuals have familial hypercholesterolemia (FH), a genetic condition in which mutations — most commonly in the LDLR, APOB, or PCSK9 genes — impair the body's ability to clear LDL particles from the bloodstream.

Heterozygous FH (HeFH), in which a person inherits one defective copy of the gene, is among the most common serious genetic disorders on the planet. People with HeFH typically have LDL-C levels of 190-400 mg/dL — roughly two to four times the normal range. Without treatment, many will suffer heart attacks in their 40s or 50s. Homozygous FH (HoFH), caused by inheriting two defective copies, is rarer (about 1 in 300,000) but far more severe, with LDL-C levels that can exceed 500 mg/dL and heart attacks occurring in childhood or adolescence.

Despite being one of the most common genetic diseases, FH remains vastly underdiagnosed. Estimates suggest that fewer than 10% of people with FH worldwide have been identified, and even fewer are adequately treated.

The Limitations of Current Treatments

The therapeutic arsenal against high cholesterol has grown considerably over the past four decades:

• Statins (e.g., atorvastatin, rosuvastatin): The first-line treatment, statins block cholesterol synthesis in the liver and upregulate LDL receptors. They typically reduce LDL-C by 30-50%. But many patients experience muscle pain, fatigue, or other side effects that lead to discontinuation.

• Ezetimibe: Blocks cholesterol absorption in the gut. Adds roughly 15-20% LDL-C reduction on top of statins. Generally well-tolerated but insufficient alone for severe cases.

• PCSK9 inhibitor injections (evolocumab/Repatha, alirocumab/Praluent): Monoclonal antibodies that block the PCSK9 protein, allowing more LDL receptors to recycle to the liver cell surface. They reduce LDL-C by 50-60% and have demonstrated clear cardiovascular benefits. But they require injections every two to four weeks — indefinitely.

• Inclisiran (Leqvio): An RNA interference drug that silences PCSK9 gene expression. Requires only two injections per year after initial dosing. A significant convenience improvement, but still a lifelong treatment.

The overarching problem with all of these therapies is adherence. Studies consistently show that roughly half of patients prescribed statins stop taking them within a year. Even with injectable therapies, adherence declines over time. Every missed dose is a period during which LDL-C rebounds and atherosclerosis progresses silently.

This is the fundamental appeal of a one-time genetic treatment: you cannot forget to take a medicine that has permanently altered your biology.

How Base Editing Targets PCSK9

The PCSK9 Story: Nature's Own Experiment

The case for targeting PCSK9 is one of the most compelling examples of human genetics informing drug development in the history of medicine.

PCSK9 (proprotein convertase subtilisin/kexin type 9) encodes a protein produced primarily by the liver. Its normal function is to bind to LDL receptors (LDLR) on the surface of liver cells and tag them for destruction. Fewer LDL receptors on the cell surface means fewer LDL particles are cleared from the blood, which means higher LDL-C levels.

In 2003, researchers in France identified gain-of-function mutations in PCSK9 that caused severe hypercholesterolemia — the protein was too active, destroying too many LDL receptors. But the truly electrifying discovery came in 2005 and 2006, when studies of the Dallas Heart Study and other cohorts identified people with loss-of-function mutations in PCSK9. These individuals produced little or no functional PCSK9 protein. The consequences were remarkable:

• Their LDL-C levels were 15-40% lower than average.
• Their risk of coronary heart disease was reduced by up to 88%.
• They were otherwise healthy — suffering no apparent ill effects from having reduced or absent PCSK9 function.

One particularly striking case involved a woman of African descent who carried two loss-of-function PCSK9 mutations (compound heterozygote). Her LDL-C was just 14 mg/dL — extraordinarily low — and she was healthy, cognitively normal, and had no cardiovascular disease at age 32 when studied.

Nature had essentially performed the experiment: permanently inactivating PCSK9 is safe and profoundly protective against heart disease. The question was how to replicate that experiment therapeutically.

What Is Base Editing?

Base editing is a precision gene-editing technology developed in the laboratory of David Liu at the Broad Institute of MIT and Harvard, first described in 2016. If traditional CRISPR-Cas9 is molecular scissors — cutting both strands of DNA to make changes — then base editing is more like a molecular pencil eraser that changes a single letter without cutting the page.

A base editor is a fusion protein that combines three elements:

1. A catalytically impaired ("nickase") Cas9 that can be guided to a specific DNA sequence by a guide RNA but does not make a double-strand break.
2. A deaminase enzyme that chemically converts one DNA base to another.
3. Proteins that enhance the efficiency and precision of the edit.

There are two main classes of base editors:

• Cytosine base editors (CBEs): Convert C-G base pairs to T-A base pairs.
• Adenine base editors (ABEs): Convert A-T base pairs to G-C base pairs.

Verve's approach uses an adenine base editor (ABE) to make a single A-to-G change at a precise location in the PCSK9 gene in liver cells. This specific edit introduces a splice-site disruption — it alters the sequence that tells the cell's machinery where to cut and join the gene's messenger RNA. The result is that the liver cell can no longer produce functional PCSK9 protein.

Why Base Editing Instead of Standard CRISPR?

The advantages of base editing over conventional CRISPR-Cas9 for this application are significant:

• No double-strand breaks (DSBs): Standard CRISPR cuts both strands of DNA, relying on the cell's repair machinery to fix the break. This process is error-prone and can introduce random insertions or deletions (indels), large deletions, or even chromosomal rearrangements. Base editing avoids DSBs entirely, making it inherently safer.

• Predictable outcomes: A base edit produces a defined, single-nucleotide change — an A becomes a G at one specific position. There is no ambiguity about what the edit will look like.

• Lower risk of off-target damage: Because base editing does not activate the cell's DNA damage response pathways, the collateral damage profile is generally cleaner.

• Irreversibility as a feature: For a target like PCSK9, where lifelong inactivation is the goal, a permanent genomic change is exactly what you want. Unlike RNA-based approaches (inclisiran, siRNA), the edit does not wear off.

Delivery: Getting the Editor to the Liver

The base editor and its guide RNA are packaged inside a lipid nanoparticle (LNP) — a tiny sphere of fatty molecules that protects the RNA cargo and facilitates its uptake into cells. Verve's VERVE-102 uses an advanced LNP formulation decorated with GalNAc (N-acetylgalactosamine) ligands, which bind specifically to the asialoglycoprotein receptor (ASGPR) expressed abundantly on the surface of hepatocytes (liver cells). This targeting mechanism ensures that the vast majority of LNPs are taken up by the liver, minimizing off-target editing in other tissues.

The treatment is administered as a single intravenous (IV) infusion, typically over about an hour. The LNPs circulate in the bloodstream, home to the liver, and deliver their payload. Inside the hepatocyte, the base editor makes its single-letter change, the mRNA is degraded within hours, and the edit remains — permanently inscribed in the cell's genome.

From VERVE-101 to VERVE-102: Lessons Learned

VERVE-101 and the Heart-1 Trial

Verve's journey to the clinic began with VERVE-101, the company's first-generation base editing therapy targeting PCSK9. The Heart-1 trial (NCT05398029), launched in 2022, was a first-in-human, Phase 1 dose-escalation study conducted primarily in New Zealand and the United Kingdom. It enrolled adults with HeFH and established atherosclerotic cardiovascular disease (ASCVD) who were already on maximally tolerated lipid-lowering therapy.

Heart-1 provided critical proof-of-concept data:

• The treatment successfully edited PCSK9 in human liver cells in vivo.
• Dose-dependent reductions in blood PCSK9 protein and LDL-C were observed.
• At the highest doses tested, PCSK9 protein was reduced by approximately 47% and LDL-C by approximately 39%.

However, VERVE-101 also revealed limitations. The LNP used in the first-generation product lacked the optimized liver-targeting capability of later formulations, which meant that higher doses were needed to achieve clinically meaningful editing efficiency. There were also transient elevations in liver enzymes (ALT and AST) in some participants — a signal that the LNP was causing some degree of liver inflammation. One participant at the highest dose level experienced a serious cardiovascular event, though the independent data safety monitoring board determined it was unrelated to treatment.

The Heart-1 results, presented at the American Heart Association Scientific Sessions in November 2023, were enough to demonstrate that in vivo base editing of PCSK9 was feasible and could lower cholesterol in humans. But they also made clear that a better delivery vehicle was needed.

VERVE-102: The Next-Generation Approach

VERVE-102 represents Verve's second-generation therapy, incorporating several key improvements:

• Optimized LNP formulation: A new lipid nanoparticle with improved potency, allowing lower doses to achieve higher editing efficiency.
• GalNAc targeting: The addition of GalNAc ligands to the LNP surface dramatically increases liver specificity. This means more of the drug reaches hepatocytes and less ends up in non-target tissues — improving both efficacy and safety.
• Same base editing payload: The adenine base editor and guide RNA targeting the PCSK9 splice site remain the same proven components.

The FDA cleared the Investigational New Drug (IND) application for VERVE-102 in March 2025, allowing the Heart-2 trial to proceed in the United States — a significant milestone, as it marked the first FDA-authorized clinical trial of an in vivo base editing therapy for cardiovascular disease.

Heart-2 Trial Design

The Heart-2 trial (Phase 1b) was designed as a dose-escalation study in adults with HeFH and clinical ASCVD, or at very high cardiovascular risk, who remained above their LDL-C treatment goals despite maximal conventional therapy. Participants continued their existing lipid-lowering medications (statins, ezetimibe, PCSK9 inhibitors) and received a single IV infusion of VERVE-102 on top of that standard regimen.

The trial evaluated three ascending dose levels: 0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg — all substantially lower than the doses tested with VERVE-101, thanks to the improved LNP.

The Heart-2 Results

The Heart-2 data, first presented in early 2026, represent a landmark moment for the field of in vivo gene editing. Here is what the trial showed.

Efficacy: Deep, Dose-Dependent LDL-C Reduction

A total of 14 participants were treated across the three dose cohorts. The results demonstrated clear dose-dependent reductions in both PCSK9 protein and LDL-C:

Dose Level	PCSK9 Reduction	Mean LDL-C Reduction	Maximum LDL-C Reduction
0.3 mg/kg	Modest	~30%	~39%
0.45 mg/kg	Moderate	~44%	~55%
0.6 mg/kg	Substantial	~53%	69%

At the highest dose tested (0.6 mg/kg), participants achieved a mean LDL-C reduction of approximately 53%, with the maximum individual reduction reaching 69%. These reductions were observed on top of existing lipid-lowering therapy — meaning participants who were already taking statins, ezetimibe, or even PCSK9 inhibitor injections saw their LDL-C drop by an additional half or more.

To put these numbers in context:

• A 53% mean reduction from a single infusion matches or exceeds the LDL-C lowering typically seen with PCSK9 inhibitor injections (evolocumab or alirocumab), which achieve roughly 50-60% reduction but require injections every 2-4 weeks for life.
• A 69% maximum reduction surpasses what most patients achieve with any single cholesterol-lowering therapy.
• The reductions appeared durable through the follow-up period, consistent with a permanent genomic edit rather than a transient pharmacological effect.

Safety: A Clean Profile

Perhaps even more impressive than the efficacy was the safety profile:

• Zero treatment-related serious adverse events (SAEs) were reported across all 14 participants and all dose levels.
• There were no clinically significant laboratory abnormalities — including no meaningful elevations in liver enzymes (ALT, AST), which had been a concern with VERVE-101.
• Infusion-related reactions were mild and manageable.
• No evidence of off-target editing was detected in the analyses performed.

The clean safety profile at the 0.6 mg/kg dose — the dose that achieved the most robust LDL-C lowering — is particularly encouraging. It suggests that the GalNAc-targeted LNP is delivering the base editor efficiently to the liver without causing the inflammatory responses that plagued earlier LNP formulations.

What the Data Mean

The Heart-2 results are significant for several reasons:

1. Proof that in vivo base editing can achieve clinically meaningful LDL-C reduction in humans. A 53-69% reduction in LDL-C, if durable, would be expected to translate into a substantial reduction in cardiovascular events over a patient's lifetime.

2. Validation of the GalNAc-LNP platform. The improved safety and potency of VERVE-102 compared to VERVE-101 demonstrate that targeted LNP delivery can solve the tolerability challenges that limited the first-generation product.

3. One-time dosing works. Unlike every existing cholesterol therapy — which requires ongoing administration — VERVE-102 was given once and appears to produce a lasting effect. If confirmed in longer follow-up and larger trials, this represents a paradigm shift in cardiovascular medicine.

Eli Lilly's Bet on Gene Editing

The Partnership

In a move that sent shockwaves through the pharmaceutical industry, Eli Lilly entered a major partnership with Verve Therapeutics, gaining rights to VERVE-102 and Verve's broader cardiovascular gene-editing pipeline. The deal, valued at up to several billion dollars including upfront payment and milestone-based payments, represented one of the largest investments by a major pharmaceutical company in the gene-editing space.

Eli Lilly's interest is not difficult to understand. The company has been aggressively building its pipeline in cardiometabolic disease, and a one-time genetic cure for high cholesterol represents the ultimate competitive advantage in a market crowded with chronic therapies.

Why Big Pharma Is Investing in One-Time Genetic Medicines

The Lilly-Verve partnership reflects a broader strategic shift in the pharmaceutical industry. For decades, the most profitable drugs have been those taken chronically — statins, blood pressure medications, diabetes drugs. A one-time cure would seem to undermine that business model. So why is Lilly betting on it?

Several factors are converging:

• Patent cliffs: Many blockbuster chronic therapies are facing generic competition. A differentiated one-time treatment offers a new revenue stream.
• Payer dynamics: Health insurers and national health systems are increasingly willing to pay large upfront costs for curative therapies that eliminate decades of ongoing treatment expenses. The math is simple: a $100,000 one-time treatment that prevents 30 years of PCSK9 inhibitor injections ($14,000/year) plus hospitalizations for heart attacks saves the system money.
• Competitive moats: Gene-editing medicines are extraordinarily difficult to develop and manufacture, creating high barriers to entry for generic competitors.
• First-mover advantage: The company that establishes the first approved one-time cholesterol treatment will likely capture a dominant market share that persists for years.

Market Implications

The global cholesterol-lowering drug market exceeds $20 billion annually, and the cardiovascular therapeutic area as a whole is worth far more. If VERVE-102 or a successor product achieves regulatory approval:

• It could disrupt the PCSK9 inhibitor market (evolocumab and alirocumab generate billions in annual sales) by offering a one-time alternative.
• It could expand the treatable population by reaching patients who refuse or cannot adhere to chronic therapies.
• It could redefine pricing models in cardiovascular medicine, with outcomes-based contracts tied to durable LDL-C reduction.

Challenges and Open Questions

Despite the excitement surrounding the Heart-2 results, important questions remain before in vivo base editing can become a standard treatment for high cholesterol.

Durability: Will the Edit Last a Lifetime?

The central premise of VERVE-102 is that a permanent genomic edit will produce a permanent therapeutic effect. But "permanent" is a complex concept in biology.

Hepatocyte turnover is the key variable. Liver cells are long-lived but not immortal. In a healthy adult liver, hepatocytes turn over slowly, with an estimated half-life of 200-300 days (though many cells persist much longer). The edited cells will gradually be replaced by new hepatocytes derived from liver progenitor cells — and those progenitor cells may or may not carry the edit, depending on whether they were transduced by the LNP.

In preclinical studies in non-human primates, Verve has shown durable PCSK9 knockdown and LDL-C reduction persisting for over two years — the longest time points studied — with no evidence of the effect waning. This is encouraging, but primates are not humans, and two years is not a lifetime.

The Heart-2 trial will continue to follow participants for long-term durability data. If some loss of effect is observed over years, the question becomes whether a second infusion could "top up" the edit — and whether re-dosing with an LNP would trigger immune responses.

The Irreversibility Question

A permanent edit is a feature when you are right about the target. But what if, hypothetically, we discover that PCSK9 serves an important function we have not yet appreciated?

The reassurance here comes from human genetics. People born with complete PCSK9 loss of function have been studied for decades and appear healthy. The woman with an LDL-C of 14 mg/dL was cognitively and physically normal. Epidemiological studies of PCSK9 loss-of-function carriers — numbering in the thousands — have not revealed unexpected health consequences.

That said, the longest-studied PCSK9-deficient individuals are still only in their 60s and 70s. Effects that emerge only in extreme old age, or in specific clinical contexts (such as severe infection or liver disease), cannot be entirely excluded. This is a theoretical concern, but it warrants honesty.

Immunogenicity and Re-Dosing

Lipid nanoparticles can trigger immune responses, particularly the production of anti-PEG antibodies (since most LNP formulations contain PEGylated lipids). If a patient develops anti-PEG antibodies after the first infusion, a second dose could be less effective or cause allergic reactions.

For a treatment that is designed to work in a single dose, this may be a moot point — but it becomes relevant if re-dosing is ever needed, or if the patient later requires a different LNP-based therapy (including mRNA vaccines, which also use LNPs).

Verve's GalNAc-targeted LNP may mitigate some immunogenicity concerns by enabling lower doses, but this is an area that will require ongoing monitoring.

Off-Target Editing

Any gene-editing therapy carries the theoretical risk of editing unintended genomic sites. Base editors, while generally more precise than standard CRISPR-Cas9, can cause bystander edits (editing nearby bases within the editing window) and guide-RNA-independent off-target deamination (the deaminase acting on RNA or DNA at sites not directed by the guide RNA).

Verve has conducted extensive off-target analyses using techniques like GUIDE-seq and CIRCLE-seq, and has not identified clinically concerning off-target editing. But the sensitivity of these assays has limits, and very rare off-target events could be missed. Long-term follow-up of treated patients, including cancer surveillance, will be essential.

Cost and Access

Gene therapies and gene-editing medicines have historically been priced in the range of $500,000 to $3.5 million per treatment (e.g., Zolgensma at $2.1 million, Casgevy at $2.2 million). A one-time cholesterol treatment would need to be priced much lower to be economically viable for a condition affecting 1 in 250 people.

Analysts have speculated that VERVE-102 could be priced in the range of $50,000 to $200,000 — expensive but potentially cost-effective compared to decades of PCSK9 inhibitor therapy plus the costs of treating cardiovascular events.

The bigger question is global access. FH is a worldwide disease, but gene-editing medicines require sophisticated manufacturing, cold-chain storage and distribution, and specialized medical infrastructure for administration and monitoring. Ensuring that patients in low- and middle-income countries — where cardiovascular disease burden is greatest — can access these therapies is a challenge the field has not yet solved.

Pediatric Applications

FH causes atherosclerosis from birth, and damage accumulates throughout childhood. The earlier you intervene, the greater the lifetime benefit. But administering a permanent gene edit to a child raises unique ethical and safety considerations:

• Can informed consent be obtained for a permanent genomic change in a minor?
• Are there developmental effects of very low PCSK9/LDL-C in growing children?
• The safety database needed for pediatric approval will be substantially more demanding.

Pediatric applications are likely years away but represent an important long-term goal, particularly for children with homozygous FH who face the highest risk.

What's Next

Phase 2 and Beyond

Based on the Heart-2 results, Verve and Eli Lilly are expected to advance VERVE-102 into a Phase 2 trial in the second half of 2026. This larger study will likely:

• Enroll a broader population of HeFH patients, potentially including those without prior cardiovascular events.
• Confirm the optimal dose (likely at or near 0.6 mg/kg).
• Gather more robust durability data over 12-24 months of follow-up.
• Begin building the safety database needed for eventual regulatory approval.

A Phase 3 pivotal trial could begin as early as 2027-2028, with a potential regulatory filing in 2029-2030. If approved, VERVE-102 would be the first in vivo gene-editing therapy for a common chronic disease — a distinction that would reshape the field.

Broader Cardiovascular Applications

PCSK9 is just the beginning. The same base-editing platform could theoretically be applied to other cardiovascular targets:

• ANGPTL3: Another liver-expressed gene whose inactivation lowers LDL-C, triglycerides, and other atherogenic lipoproteins. Verve has a preclinical program targeting ANGPTL3 that could address patients who do not respond to PCSK9 knockdown alone.

• LPA (lipoprotein(a)): Elevated Lp(a) is an independent cardiovascular risk factor affecting roughly 20% of the global population. There is currently no approved therapy specifically targeting Lp(a), making it an attractive gene-editing target.

• Hypertension targets: Genes involved in blood pressure regulation could potentially be edited to provide lasting blood pressure control.

The Competitive Landscape

Verve is not the only company pursuing genetic approaches to cardiovascular disease:

• Alnylam Pharmaceuticals markets inclisiran (Leqvio), an siRNA therapy that silences PCSK9 expression with twice-yearly injections. While not a permanent edit, it represents the closest approved competitor in terms of mechanism.

• Intellia Therapeutics has preclinical programs using in vivo CRISPR to target liver-expressed genes, though their lead cardiovascular program trails Verve's.

• Beam Therapeutics, co-founded by base editing inventor David Liu, has its own base-editing platform but has focused primarily on hematological diseases rather than cardiovascular targets.

• Prime Medicine is developing prime editing approaches that could theoretically offer even more precise genomic modifications, though their cardiovascular pipeline is early-stage.

Verve's first-mover advantage in in vivo base editing for CVD, combined with Eli Lilly's commercial infrastructure, positions the company well — but the race is far from over.

Frequently Asked Questions

What is base editing for heart disease and how does it work?

Verve Therapeutics uses an adenine base editor to make a single A-to-G change in the PCSK9 gene in liver cells, disrupting a splice site so the liver can no longer produce functional PCSK9 protein. Since PCSK9 normally destroys LDL receptors on liver cells, knocking it out allows more LDL cholesterol to be cleared from the bloodstream. The editor is delivered via a GalNAc-targeted lipid nanoparticle in a single IV infusion.

How much did Verve's VERVE-102 therapy lower cholesterol?

In the Heart-2 Phase 1b trial, 14 participants were treated across three dose levels. At the highest dose (0.6 mg/kg), patients achieved a mean LDL-C reduction of approximately 53%, with the maximum individual reduction reaching 69%. These reductions were on top of existing lipid-lowering therapy, and there were zero treatment-related serious adverse events across all dose levels.

Is Verve's base editing treatment a one-time cure?

Yes, VERVE-102 is designed as a one-time treatment. Because the base editor makes a permanent change to the DNA in liver cells, the effect does not wear off like daily statins or biweekly PCSK9 inhibitor injections. In preclinical studies in non-human primates, durable PCSK9 knockdown and LDL-C reduction persisted for over two years with no evidence of the effect waning, though lifetime durability in humans remains to be confirmed.

How does Verve's base editing compare to statins and PCSK9 inhibitors?

Statins typically reduce LDL-C by 30-50% but require daily pills, and roughly half of patients stop taking them within a year. PCSK9 inhibitor injections (evolocumab, alirocumab) achieve 50-60% reduction but require injections every 2-4 weeks indefinitely. VERVE-102 achieved a comparable or superior 53-69% LDL-C reduction from a single infusion, eliminating the adherence problem that undermines all chronic therapies.

When could Verve's base editing therapy be available to patients?

Verve and Eli Lilly are expected to advance VERVE-102 into a Phase 2 trial in the second half of 2026, with a Phase 3 pivotal trial potentially beginning in 2027-2028 and a regulatory filing possible in 2029-2030. If approved, VERVE-102 would be the first in vivo gene editing therapy for a common chronic disease. The FDA cleared the IND for VERVE-102 in March 2025, making it the first FDA-authorized clinical trial of an in vivo base editing therapy for cardiovascular disease.

The Bottom Line

The Heart-2 trial results for VERVE-102 represent a genuine inflection point in medicine. For the first time, a single intravenous infusion of a base-editing therapy has achieved clinically meaningful LDL-C reductions — up to 69% — in patients with familial hypercholesterolemia, with a clean safety profile and the realistic prospect of durability.

This is not the end of the road. Larger, longer trials are needed. Durability must be confirmed over years, not months. Questions about cost, access, immunogenicity, and long-term safety remain open. Regulatory approval is likely still several years away.

But the direction of travel is unmistakable. We are moving from a world in which heart disease prevention requires a lifetime of daily pills and regular injections to one in which a single treatment — a precise, one-letter change in a single gene — can fundamentally alter a patient's cardiovascular trajectory.

The 700,000 Americans who die of heart disease each year, and the hundreds of millions more who live with elevated cardiovascular risk, deserve better options than we have today. Base editing may be one of the most important of those options. And with the Heart-2 data in hand, the path from promise to reality has never looked clearer.

Sources & Further Reading

• Verve Therapeutics. "Heart-2 Phase 1b Clinical Trial Results for VERVE-102." Corporate press release, 2026.

• Musunuru K, et al. "In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates." Nature, 2021; 593:429-434.

• Cohen JC, et al. "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease." New England Journal of Medicine, 2006; 354:1264-1272.

• Zhao Z, et al. "Lifelong absence of PCSK9 expression: a compound heterozygous loss-of-function case." Arteriosclerosis, Thrombosis, and Vascular Biology, 2006; 26(12):2614-2621.

• Gaudelli NM, et al. "Programmable base editing of A-T to G-C in genomic DNA without DNA cleavage." Nature, 2017; 551:464-471.

• Komor AC, et al. "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." Nature, 2016; 533:420-424.

• Nissen SE, et al. "LDL cholesterol lowering and cardiovascular outcomes: a systematic review." Journal of the American Medical Association, 2024.

• Raal FJ, et al. "Inclisiran for the treatment of heterozygous familial hypercholesterolemia." New England Journal of Medicine, 2020; 382:1520-1530.

• Khera AV, et al. "Association of rare and common variation in the lipoprotein(a) gene with coronary artery disease." JAMA, 2017; 317(9):937-946.

• American Heart Association. Heart Disease and Stroke Statistics — 2025 Update. Circulation, 2025.

• World Health Organization. "Cardiovascular Diseases (CVDs)." Fact sheet, 2024.

• Eli Lilly and Company. "Strategic Partnership with Verve Therapeutics." Investor presentation, 2025.